Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?
Several endocrine disorders have been associated with an increased risk of cardiovascular disease (CVD) and mortality. In addition, even subtle hormonal disturbances may modulate the function of cardiovascular organs. In this article, we discuss in detail the contribution of thyroid hormones, cortisol, the somatotropic hormones, and prolactin in the development of CVD. We do not only discuss epidemiological evidence on the association between hormones and cardiovascular disease, but we also address possible pathophysiological mechanisms underlying this association. In fact, hormones can contribute to the development of CVD both indirectly by inducing secondary metabolic changes such as hypertension, insulin resistance, or dyslipidemia, and directly by modulation of cellular pathways that are important in the process of atherosclerotic plaque formation (atherogenesis), plaque instability, and thrombosis. To date several new therapeutic approaches that focus on the control of hormones at the tissue level, independently of their circulating levels, are being developed. These may offer new possibilities for cardiovascular risk reduction.
van Zaane
Bregje
B
Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Reuwer
Anne Q
AQ
Büller
Harry R
HR
Kastelein
John J P
JJ
Gerdes
Victor E A
VE
Twickler
Marcel Th B
MT
D000818:Animals; D050197:Atherosclerosis / Q000209:etiology*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000209:etiology* / Q000517:prevention & control; D003480:Cushing Syndrome / Q000401:mortality; D013006:Growth Hormone / Q000502:physiology; D006728:Hormones / Q000502:physiology*; D006801:Humans; D006854:Hydrocortisone / Q000502:physiology; D012307:Risk Factors; D013963:Thyroid Hormones / Q000502:physiology
D006728:Hormones; D013963:Thyroid Hormones; D013006:Growth Hormone; D006854:Hydrocortisone